Pet imaging to define mechanisms and stratify risk in arrhythmogenic cardiomyopathy

Active Grant Awarded

Award ID
R01HL188047
Recipient
Awarding agency
Obligated
$705,239

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 4% complete
Place of performance
Salt Lake City, UT 84112, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Heart Lung and Blood Institute (National Institutes of Health) awarded the University of Utah a grant of $705,239 on September 2, 2026, under Assistance Listing 93.837, Cardiovascular Diseases Research, for the project "PET Imaging to Define Mechanisms and Stratify Risk in Arrhythmogenic Cardiomyopathy" (Grant R01HL188047). The project tests whether FDG PET signal in arrhythmogenic cardiomyopathy reflects immune cell infiltration of the myocardium, using mouse models. Aim 1 defines the immune and cardiac cell populations behind FDG uptake, testing whether global macrophage proliferation accounts for the signal and whether CCR2 subsets drive disease progression. Aim 2 uses a CCR2-targeted PET radiotracer to image pathogenic macrophages in vivo and links those findings to arrhythmia burden, ventricular remodeling, and survival. Dollars obligated match the total of $705,239. The period of performance runs from the September 2, 2026 award date to an ultimate completion date of May 31, 2031. Place of performance is Salt Lake City, UT 84112. Pennsylvania State University, doing business as Penn State Milton S. Hershey Medical Center, holds a sub-award under this grant (R01HL188047-10079361-02-PSU), dated November 6, 2026, for the same PET imaging project.

Description

Abstract
Arrhythmogenic cardiomyopathy (ACM) is a heritable heart disease characterized by lethal arrhythmias, progressive heart failure, and sudden cardiac death in otherwise young, healthy individuals. Although causative mutations in desmosomal proteins have been identified, there remains no reliable way to predict which mutation carriers will develop disease. This lack of prognostic tools leaves patients and families without effective risk-stratification strategies. Positron emission tomography (pet) using [18F]fluorodeoxyglucose (FDG) detects myocardial inflammation and hypermetabolism. Both our preliminary work and published studies demonstrate increased FDG uptake in ACM, but the clinical significance and underlying cellular sources of this signal remain unclear. Our central hypothesis is that pet imaging can serve as a non-invasive predictive imaging tool to detect and predict ACM disease development and progression. We propose that FDG uptake reflects immune cell infiltration within the myocardium, and that CCR2⁺ monocyte-derived macrophages represent a critical population driving arrhythmias, ventricular remodeling, and adverse outcomes. To test this hypothesis, we will integrate molecular imaging, immune profiling, and cardiac physiology in mechanistically relevant mouse models of ACM. In aim 1, we will define the immune and cardiac cell populations responsible for FDG uptake, testing whether global macrophage proliferation accounts for the pet signal while CCR2⁺ subsets determine disease progression. In aim 2, we will utilize targeted CCR2 immune pet with a radiotracer specific to CCR2-positive cells to directly image pathogenic macrophages in vivo, and we will link these imaging findings to arrhythmia burden, ventricular remodeling, and survival. Together, these studies will establish immune pet as a powerful tool to noninvasively monitor disease activity and progression in a preclinical mode of ACM. By bridging mechanistic biology with translational imaging, this project will clarify the cellular basis of FDG uptake, validate CCR2-pet as a novel diagnostic approach, and provide the foundation for future strategies to stratify risk and target inflammation in ACM.

Subawards

Subrecipient Amount Awarded
Pennsylvania State University PET Imaging to Define Mechanisms and Stratify Risk in Arrhythmogenic Cardiomyopathy $54,970

Quick answers

Who received award R01HL188047?

R01HL188047 was awarded to University Of Utah by National Heart Lung and Blood Institute (National Institutes of Health) on September 2, 2026.

How much is award R01HL188047 worth?

$705,239 has been obligated on R01HL188047.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award